Burke Pharmaceutical Research

1. Takeda Pharmaceuticals U.S.A., Inc. $363,140 34 payments
2. Incyte Corporation $332,426 120 payments
3. Amgen Inc. $267,517 16 payments
4. AbbVie, Inc. $256,655 66 payments
5. E.R. Squibb & Sons, L.L.C. $248,405 20 payments
6. Teva Pharmaceuticals USA, Inc. $176,243 15 payments
7. Eli Lilly and Company $126,845 7 payments
8. Pfizer Inc. $105,127 31 payments
9. Celgene Corporation $91,250 2 payments
10. Aclaris Therapeutics, Inc. $89,750 12 payments

1. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $185,977 17 payments
2. Interchangeability Study - ABP 654 $155,332 4 payments
3. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $89,750 12 payments
4. A Phase 2, Multicenter, Global, Randomized, Double $88,846 1 payment
5. A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea $86,400 4 payments
6. Phase 2AB Safety and Efficacy Study of Pf06700841 in Patients With Moderate Psoriasis $81,230 22 payments
7. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy $80,049 7 payments
8. TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $77,415 3 payments
9. A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate to Severe Alopecia Areata $74,620 2 payments
10. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $70,650 9 payments

1. Patient care $11,711 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.